/
KRYS
$382.00+$3.85 (+1.02%)live
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
2
institutions
Market cap
$11.0B
29M shares
52-week range
$130.50 – $382.00
100% from low
Sector
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Exchange
NASDAQ
CS
Price (6 mo)
Loading chart…
Change+$310.23
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $1.0M | $0 | $0 | $0 | $0 | $50.7M | $290.5M | $389.1M |
| Cost of revenue | $141.0K | $974.0K | $1.9M | $0 | $0 | $3.1M | $20.1M | $28.8M |
| Gross profit | $886.0K | −$974.0K | −$1.9M | $0 | $0 | $47.6M | $270.5M | $360.4M |
| Gross margin | 86.3% | — | — | — | — | 93.9% | 93.1% | 92.6% |
| R&D | $7.8M | $15.6M | $17.9M | $27.9M | $42.5M | $46.4M | $53.6M | $58.0M |
| Operating income | −$11.9M | −$22.1M | −$33.0M | −$68.3M | −$145.2M | −$109.7M | $65.7M | $161.3M |
| EBITDA | −$10.7M | −$18.1M | −$30.3M | −$66.2M | −$116.8M | −$91.3M | $109.9M | $196.0M |
| Net income | −$10.9M | −$19.1M | −$32.2M | −$69.6M | −$140.0M | $10.9M | $89.2M | $204.8M |
| Net margin | -1060.3% | — | — | — | — | 21.6% | 30.7% | 52.6% |
| EPS (diluted) | -0.97 | -1.20 | -1.71 | -3.13 | -5.49 | 0.39 | 3.00 | 6.84 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $519M | $7.67 | $6.22–$8.79 | 8 |
| 2027 | $660M | $9.69 | $6.14–$12.34 | 7 |
| 2028 | $848M | $12.76 | $7.01–$21.09 | 5 |
| 2029 | $1.3B | $25.18 | $23.53–$26.87 | 1 |
Forward consensus · source: Financial Modeling Prep
DCF fair valuemodel estimate
Intrinsic value
$560.30
Price
$382.00
Implied upside
+47%
Peer comparison
Krystal Biotech, Inc. Common Stock
Krystal Biotech Inc is an integrated, commercial-stage biotechnology company focused on the discovery, development, manufacturing, and commercialization of genetic medicines to treat diseases with high unmet medical needs. The company uses its patented HSV-1-based gene therapy platform to create vectors that deliver therapeutic transgenes to target cells. It possesses exclusive rights to develop, manufacture, and commercialize VYJUVEK internationally. The company operates as one operating segment focused on pharmaceutical products and manufactures, markets, and sells VYJUVEK in the United States and markets and sells VYJUVEK in the European Union, and Japan.
www.krystalbio.com- Employees
- 295
- IPO / List date
- Sep 20, 2017
- HQ
- PITTSBURGH, PA
Held by traders on TradeandTell
No one on the platform currently holds KRYS.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Bridgewater Associatesas of 2026-03-31 | 46,367 | $12.0M |
| Renaissance Technologiesas of 2026-03-31 | 9,600 | $2.5M |
Insider activity (SEC Form 4)
Recent trades on TradeandTell
No one on the platform has traded KRYS yet.
